Zydus Lifesciences · NSE: ZYDUSLIFE · BSE: 532321

Q1 FY26 results · Apr–Jun 2025

Zydus Lifesciences reported revenue from operations of ₹6,573.70 crore (up 5.9% from Q1 FY25) and net profit of ₹1,521.00 crore (up 2.6% from Q1 FY25) for Q1 FY26 (Apr–Jun 2025), on a consolidated basis.

Consolidated · ₹ crore
Item	Q1 FY26	Q1 FY25	YoY	Q4 FY25	QoQ
Revenue from operations	6,573.70	6,207.50	+5.9%	6,527.90	+0.7%
Other income	154.90	63.20	+145.1%	80.60	+92.2%
Total income	6,728.60	6,270.70	+7.3%	6,608.50	+1.8%
Profit before share of associates & JVs and tax	1,920.60	1,899.70	+1.1%	1,672.00	+14.9%
Share of profit/(loss) of associates & JVs	34.40	18.90		(5.10)
Net profit for the period	1,521.00	1,482.50	+2.6%	1,243.70	+22.3%
Attributable to shareholders of the company	1,466.80	1,419.90	+3.3%	72.80	20x
EPS, basic (₹)	14.58	14.11	+3.3%	11.64	+25.3%
Net margin (%)	23.1	23.9		19.1

This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.

Standalone · ₹ crore
Item	Q1 FY26	Q1 FY25	YoY	Q4 FY25	QoQ
Revenue from operations	2,588.30	4,160.20	−37.8%	5,819.60	−55.5%
Other income	157.10	106.60	+47.4%	185.40	−15.3%
Total income	2,745.40	4,266.80	−35.7%	6,005.00	−54.3%
Profit before tax	474.90	2,233.50	−78.7%	3,674.70	−87.1%
Net profit for the period	384.70	1,700.80	−77.4%	2,813.70	−86.3%
EPS, basic (₹)	3.82	16.90	−77.4%	27.96	−86.3%
Net margin (%)	14.9	40.9		48.3

Consolidated

Filed with BSE: 12 Aug 2025, 17:05 IST
Board meeting: 12 Aug 2025
Period: 01 Apr 2025 to 30 Jun 2025
Review status: Unaudited
Source: XBRL filing on BSE

Standalone

Filed with BSE: 12 Aug 2025, 17:05 IST
Board meeting: 12 Aug 2025
Period: 01 Apr 2025 to 30 Jun 2025
Review status: Unaudited
Source: XBRL filing on BSE